EP Patent

EP3521293A1 — Process for the preparation of an inhibitor of phosphodiesterase 4

Assigned to Dipharma Francis SRL · Expires 2019-08-07 · 7y expired

What this patent protects

The present invention relates to a process for the preparation of Crisaborole in a particular crystalline form 1 as an inhibitor of phosphodiesterase 4, in particular of phosphodiesterase 4B (PDE4B), and intermediates useful for its preparation. The claimed process is characteriz…

USPTO Abstract

The present invention relates to a process for the preparation of Crisaborole in a particular crystalline form 1 as an inhibitor of phosphodiesterase 4, in particular of phosphodiesterase 4B (PDE4B), and intermediates useful for its preparation. The claimed process is characterized by preparing the Crisaborole by hydrolysis of the C-C-alkyl ester of formula (X):The crystalline Form 1 is characterized by an XRPD spectrum wherein the most intense peaks, measured using Cu Kα radiation (λ = 1.54 Å), fall at 6.0, 12.1, 14.1, and 15.4 ± 0.2° in 2θ.

Drugs covered by this patent

Patent Metadata

Patent number
EP3521293A1
Jurisdiction
EP
Classification
—
Expires
2019-08-07
Drug substance claim
No
Drug product claim
No
Assignee
Dipharma Francis SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.